Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels

Details for Australian Patent Application No. 2005309274 (hide)

Owner The University of British Columbia

Inventors Gleave, Martin; Zupi, Gabriella

Agent Freehills

Pub. Number AU-B-2005309274

PCT Pub. Number WO2006/056054

Priority 60/522,960 24.11.04 US; 60/522,948 23.11.04 US

Filing date 22 November 2005

Wipo publication date 1 June 2006

Acceptance publication date 21 July 2011

International Classifications

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/056054 Priority application(s): WO2006/056054

21 July 2011 Application Accepted

  Published as AU-B-2005309274

17 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005309275-Method of delivery of therapeutic metal ions, alloys and salts

2005309273-Method and apparatus for gasifying solid organic materials using a side feed/centre ash dump system